4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines Silvina Laura LompardíaMariángeles DíazSilvia Elvira Hajos PRECLINICAL STUDIES 08 October 2016 Pages: 1 - 10
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) Kit Man WongLindsey N. MicelS. Gail Eckhardt PRECLINICAL STUDIES 25 October 2016 Pages: 11 - 25
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma Augusto Faria AndradeKleiton Silva BorgesLuiz Gonzaga Tone PRECLINICAL STUDIES 26 October 2016 Pages: 26 - 36
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer Noboru YamamotoYutaka FujiwaraMakoto Nishio PHASE I STUDIES 27 August 2016 Pages: 37 - 46
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors Alex A. AdjeiPatricia LoRussoViviana Bózon PHASE I STUDIES Open access 21 September 2016 Pages: 47 - 58
Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience Manojkumar BupathiJoud HajjarAung Naing PHASE I STUDIES 29 September 2016 Pages: 59 - 67
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan James M. ClearyAutumn J. McReeW. Michael Korn PHASE I STUDIES 16 November 2016 Pages: 68 - 78
Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials Emilie BoissierOlivier MirBenoît Rousseau PHASE I STUDIES 25 October 2016 Pages: 79 - 86
Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer Murtuza RampurwalaKari B. WisinskiAmye J. Tevaarwerk PHASE I STUDIES 08 November 2016 Pages: 87 - 94
A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers Laura W. GoffDana B. CardinJordan Berlin PHASE I STUDIES Open access 16 November 2016 Pages: 95 - 104
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody Nobuaki MamesayaHirotsugu KenmotsuToshiaki Takahashi SHORT REPORT Open access 06 September 2016 Pages: 105 - 107
Evaluating the role of phase I expansion cohorts in oncologic drug development Robin E. NorrisMohadese BehtajAfshin Dowlati SHORT REPORT 07 October 2016 Pages: 108 - 114
A photodynamic bifunctional conjugate for prostate cancer: an in vitro mechanistic study Valentina RapozziGreta VarchiLuigi E. Xodo SHORT REPORT 11 October 2016 Pages: 115 - 123
Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma Augusto Faria AndradeKleiton Silva BorgesLuiz Gonzaga Tone Erratum 29 November 2016 Pages: 124 - 124